arsenic trioxide / Generic mfg. - LARVOL DELTA

Severe Gout During Arsenic Therapy: Insights on Oxidative Stress and Interleukin-1β in Gout. (PubMed, ACR Open Rheumatol) - "We report a 49-year-old male patient with a normal serum uric acid and recent diagnosis of acute promyelocytic leukemia (APL) who developed a severe polyarticular gout flare during treatment with arsenic trioxide (ATO)...The gout flare in our patient was initially treated with high-dose intravenous glucocorticoids with no clinical response and was subsequently treated with interleukin-1β receptor blockade, which resulted in complete clinical resolution of his gout. Our case offers insights into inflammatory pathways in gout, including the evolving role of ROS in autoinflammation."

Journal • Acute Promyelocytic Leukemia • Gout • Hematological Malignancies • Inflammatory Arthritis • Leukemia • Oncology • Rheumatology • IL1B

Arsenic Trioxide and All-Trans Retinoic Acid Combination Therapy for the Treatment of High-Risk Acute Promyelocytic Leukemia: Results From the APOLLO Trial. (PubMed, J Clin Oncol) - P3 | "The results of the APOLLO trial support the use of ATO and ATRA for the treatment of newly diagnosed patients with high-risk APL."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Infectious Disease • Leukemia • Novel Coronavirus Disease • Oncology

Arsenic trioxide allosterically inhibits human telomerase, validated by in-silico and in-vitro cancer and non cancer cell lines. (PubMed, Sci Rep) - No abstract available

Journal • Preclinical • Hepatocellular Cancer • Oncology • Solid Tumor

Pro-ATO/Allicin Liposomes for Dual-Pathway Targeting of p53-Mutant Tumors. (PubMed, Adv Sci (Weinh)) - "Although arsenic trioxide (ATO) can restore transcriptional activity of structural p53 mutants, its clinical application is limited by subtype selectivity and systemic toxicity...Upon tumor-specific release, allicin-mediated redox activation converts As5+ to cytotoxic As3+, enabling selective p53 reactivation, concurrent ATR inhibition, and H2S-amplified apoptosis. AsAcP@LP exhibits synergistic antitumor efficacy with favorable tolerability, providing a rational nanotherapeutic strategy for p53-mutant cancers."

Journal • P53mut • Lung Cancer • Oncology • Solid Tumor • TP53

Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia. (PubMed, Cancer) - P2 | "The combination of ATO-ATRA and GO was curative in 94% of patients who had APL with a favorable safety profile (ClinicalTrials.gov identifier NCT01409161)."

Journal • P2 data • Acute Promyelocytic Leukemia • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Oncology

Corrosion of Carbon Steel in an Arsenic Trioxide Reduction Atmosphere Using Carbonaceous Materials for Elemental Arsenic Production. (PubMed, Materials (Basel)) - "The important source of C responsible for initiating corrosion was solid-state C particles originating from reused materials from previous batches. Additionally, owing to the high processing temperature, oxygen (O) was transferred to the inner side of the steel wall before the dramatical corrosion of the matrix by elemental As and C. Results of this study provide references to increase the lifespan of steel reactors for elemental As production."

Journal • CNS Disorders • Psychiatry

FIRST RESULTS OF THE APOLLO TRIAL: A RANDOMIZED PHASE III STUDY TO COMPARE ATO COMBINED WITH ATRA VERSUS STANDARD AIDA REGIMEN FOR PATIENTS WITH NEWLY DIAGNOSED, HIGH-RISK ACUTE PROMYELOCYTIC LEUKEMIA (EHA 2024) - "Background: Pioneered by the APL0406 trial (Lo-Coco et al., NEJM 2013), prior investigations have demonstrated the superiority of combining all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) over standard ATRA and chemotherapy (CHT) as front-line management of low/intermediate risk acute promyelocytic leukemia (APL)...Death in CR/CRi were observed in 0 and 3 pts in the ATRA-ATO and ATRA-CHT arm, respectively... First-line therapy with ATRA-ATO with two initial doses idarubicin results in superior EFS compared to conventional ATRA-CHT in patients with HR-APL. Further analysis of the APOLLO trial may support the implementation of this regimen as the new standard of care in patients with HR-APL"

Clinical • P3 data • Acute Promyelocytic Leukemia • Cardiovascular • Hematological Disorders • Hematological Malignancies • Infectious Disease • Leukemia • Myelodysplastic Syndrome • Novel Coronavirus Disease • Oncology • Respiratory Diseases • Septic Shock • Thrombosis

Reawakening Differentiation Therapy in Acute Myeloid Leukemia: A Comprehensive Review of ATRA-Based Combination Strategies. (PubMed, Curr Oncol) - "(3) Clinical evidence confirms that ATRA combined with arsenic trioxide or epigenetic modulators achieves high remission rates in APL and selected AML subtypes...(4) ATRA-based combination therapies represent a promising strategy to extend differentiation therapy beyond APL. This review, authored solely by the investigator, highlights molecular targets and potential enhancers warranting further clinical evaluation in AML."

Journal • Review • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Gene Therapies • Hematological Malignancies • Leukemia • Oncology • BCL2 • RARA

Obeticholic Acid and Methyl Ferulic Acid Mitigate Arsenic Trioxide-Induced Hepatotoxicity by Targeting Profibrotic and Proinflammatory Signaling. (PubMed, J Biochem Mol Toxicol) - "In conclusion, OCA and MFA mitigate ATO-induced hepatotoxicity through their antioxidant, anti-inflammatory, and anti-apoptotic mechanisms. Hence, these findings may pave the way for clinical investigation into their potential use as adjunct therapeutic agents in arsenic-induced hepatotoxicity."

IO biomarker • Journal • Hepatology • Inflammation • Liver Failure • BCL2 • IL1B • IL6 • SMAD3 • TGFB1 • TNFA

Astragalus polysaccharides inhibit arsenic trioxide-induced BMSCs damage through inhibition of Jnk and p38 signaling pathways. (PubMed, Chin Herb Med) - "The mechanisms involve suppressing ROS generation, maintaining mitochondrial membrane stability, enhancing cell viability, migration, and proliferation, as well as inhibiting Jnk and p38 mitogen-activated protein kinase (p38 MAPK) signaling pathways. The findings highlight potential molecular targets and novel strategies for the clinical prevention and treatment of ATO-related toxicity ."

IO biomarker • Journal • Hematological Malignancies • Leukemia • Oncology • BAX • CASP3 • MAPK8 • TP53

ATARI-PDAC: ATRA and SDK002 in Combination With Chemotherapy and Anti-PD-1 Inhibitor in Patients With Advanced Pancreatic Ductal Adenocarcinoma. (clinicaltrials.gov) - P1 | N=10 | Not yet recruiting | Sponsor: Daniel Breadner

New P1 trial • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma

Arsenic Trioxide Underpins Delayed Neuroinflammation and Impaired Synaptic Integrity involving Integrative Stress Response Signaling. (PubMed, bioRxiv) - "Pharmacological inhibition of the ISR with a small-molecule inhibitor, ISRIB mitigated ISR activation and preserved synaptic integrity in mouse hippocampal cells. In conclusion, our data identify ISR activation and DNA damage-driven immune dysregulation as key pathogenic drivers of ATO-induced delayed neurotoxicity and cognitive deficits and highlight ISR inhibitors as promising therapeutics to mitigate these effects."

Journal • CNS Disorders • Cognitive Disorders • Inflammation • ATF4 • STING

Influence of white blood cell count trajectories on the risk of differentiation syndrome during induction therapy with all-trans-retinoic acid and arsenic trioxide in pediatric acute promyelocytic leukemia. (PubMed, Front Pediatr) - "Furthermore, patients in Class 1 require more frequent transfusion support, including red blood cells, platelets, and plasma (p < 0.001) during induction therapy. The trajectory of WBC count during ATRA and ATO induction therapy may serve as an indicator for predicting the risk of DS in pediatric APL patients."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Frontline ATRA-ATO Therapy for Acute Promyelocytic Leukemia in Japan: Results From the Prospective Multicenter FBMTG-APL2017 Trial. (PubMed, Cancer Sci) - "All-trans retinoic acid (ATRA) combined with arsenic trioxide (ATO) has become the international standard of care for newly diagnosed acute promyelocytic leukemia (APL), demonstrating superior efficacy and safety over ATRA-chemotherapy regimens...They support its adoption as a new standard therapy and bridge the gap with established global practice. Trial Registration: Japan Registry of Clinical Trials: jRCTs071180040."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Acute Promyelocytic Leukemia Asian Consortium study of arsenic trioxide in newly-diagnosed patients: impact and outcome. (PubMed, Blood Adv) - P=N/A | "Its benefits were most obvious in frontline treatment, but were still observed during maintenance. (ClinicalTrials.gov Identifier: NCT04251754)."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Thrombocytopenia

ALLG APML5: Bioavailability and safety of oral arsenic trioxide assessed during consolidation therapy for APL. (PubMed, Blood Adv) - P1 | "In conclusion, this novel oral ATO formulation is bioequivalent with intravenous ATO and offers a convenient alternative for patients with APL. Accession Number: ACTRN12616001022459."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Assessment of Arsenic Trioxide and All-trans Retinoic Acid for the Treatment of Pediatric Acute Promyelocytic Leukemia: A Report From the Children's Oncology Group AAML1331 Trial. (PubMed, JAMA Oncol) - P3 | "Patients with high-risk APL received 4 doses of idarubicin during induction therapy only. The 2-year EFS estimates were noninferior to the historical comparator group, and advantages of the regimen included shorter treatment duration, lower exposure to anthracycline and intrathecal chemotherapy, and fewer days hospitalized. ClinicalTrials.gov Identifier: NCT02339740."

Clinical • Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Pediatrics

Obesity Worsens Arsenic Trioxide-Induced Myocardial Toxicity and Its Protection by Metallothionein. (PubMed, Cardiovasc Toxicol) - No abstract available

Journal • Acute Promyelocytic Leukemia • Genetic Disorders • Hematological Malignancies • Leukemia • Obesity • Oncology

Characterization of an Atypical PML::RARA Rearrangement: Diagnostic Utility of Optical Genome Mapping and Implications for Hematological Malignancies (ACMG 2026) - "Treatment and Management Based on this diagnosis, the patient was treated with two cycles of all-trans retinoic acid (ATRA) with arsenic trioxide (ATO) and Idarubicin. Using OGM, a cryptic t(15; 17) PML::RARA rearrangement with rare breakpoints was revealed. Additionally, the PML::RARA rearrangement was detected by FISH (82%) and karyotyping (97%)."

Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • Thrombocytopenia • BCR

Promyelocytic Blast Phase of Chronic Myeloid Leukemia: A Rare Concurrent BCR::ABL1 and PML::RARA Rearrangements Highlighting the Role of Molecular Diagnostics (ACMG 2026) - "Treatment and Management The patient was diagnosed as PBP following CML and was initiated induction cycle 1 of APML 4 including ATRA, Idarubicin and ATO in August 2025...During the PBP, a simultaneous t(15; 17)(q22; q21) translocation leads to PML::RARA fusion, providing an opportunity for treating PBP following CML with acute promyelocyte leukemia (APL) specific therapy, all-trans-retinoic acid (ATRA), and arsenic trioxide ( ATO)...CML was diagnosed in 2023 and initially managed with hydroxyurea and imatinib, but the patient was noncompliant...Therapy was switched to asciminib...Drug screening was positive for fentanyl, opiates, and methamphetamine...Cytogenetic Findings: FISH Bone marrow: positive BCR::ABL1 (90.0%) and PML::RARA (74.5%); Peripheral blood: positive BCR::ABL1 (93.0%) and PML::RARA (49.5%). Cytogenetics: 46,XY,t(9; 22)(q34; q11.2)[6]/46,idem,t(15; 17)(q24; q21)[14]."

IO biomarker • Acute Promyelocytic Leukemia • Chronic Myeloid Leukemia • Hematological Disorders • Hematological Malignancies • Immunology • Leukemia • Myeloproliferative Neoplasm • Respiratory Diseases • Rheumatology • Thrombosis • ABL1 • ANPEP • BCR • CD14 • CD2 • CD33 • CD34 • CD38 • KIT • MME • NCAM1 • PTPRC

Venetoclax induces mitochondrial apoptosis and autophagy to overcome arsenic trioxide resistance in acute promyelocytic leukemia. (PubMed, J Transl Med) - No abstract available

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology

Mechanistic Study of ATO and MET Synergistically Promoting Apoptosis in Leukemia Cells (PubMed, Zhongguo Shi Yan Xue Ye Xue Za Zhi) - "ATO combined with MET promotes apoptosis by up-regulating LKB1/AMPK and down-regulating PI3K/Akt signaling pathway to regulate the autophagy of leukemia cells."

Journal • Hematological Malignancies • Leukemia • Oncology • GLI2 • STK11

UBE2O-mediated monoubiquitination licenses NLRP6 inflammasome activation in the intestine. (PubMed, Cell Host Microbe) - "We demonstrate that the E3 ligase UBE2O catalyzes dual-site monoubiquitination of NLRP6: at K680-687 to drive oligomerization via a conformational change, and at K115/130 within the nuclear localization signal to enforce cytoplasmic sequestration through steric hindrance. Furthermore, the UBE2O inhibitor arsenic trioxide suppresses NLRP6-dependent interleukin (IL)-18 secretion in acute promyelocytic leukemia (APL) patients. Thus, UBE2O-mediated dual-site monoubiquitination emerges as a central mechanism licensing NLRP6 inflammasome activation, revealing a new target for modulating intestinal immunity."

Journal • Acute Promyelocytic Leukemia • Hematological Malignancies • Infectious Disease • Inflammation • Leukemia • Oncology • Rotavirus Infections • Targeted Protein Degradation • NLRP6

Gamma Radiation Shielding Efficiency of Cross-Linked Polystyrene-b-Polyethyleneglycol Block Copolymer Nanocomposites Doped Arsenic (III) Oxide and Boron Nitride Nanoparticles. (PubMed, Polymers (Basel)) - "At 121.8 keV, the HVL of a composite with 70 wt% As2O3 NPs is 2.00 cm, which is comparable to the HVL of lead (0.56 cm) at the same energy level. Due to the increasing need for lightweight, flexible, and lead-free shielding materials, PS-b-PEG copolymer-based nanocomposites reinforced with arsenic oxide and BN NPs will be materials of significant interest for next-generation radiation protection applications."

Journal

Integrated Proteomic and Metabolomic Profiling in Acute Promyelocytic Leukemia: Current Status and Perspectives. (PubMed, Int J Gen Med) - "Furthermore, the article explores the importance of the immune system in acute promyelocytic leukemia treatment response and the impact of all-trans retinoic acid/arsenic trioxide therapy on the proteome and metabolome. By synthesizing existing research findings, this review aims to discuss how proteomic and metabolomic data elucidate the pathological mechanisms and therapeutic targets of acute promyelocytic leukemia, providing a theoretical basis for future precision medicine and translational research."

Journal • Review • Acute Myelogenous Leukemia • Acute Promyelocytic Leukemia • Hematological Malignancies • Leukemia • Oncology • RARA